DE68911653D1 - Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie. - Google Patents

Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.

Info

Publication number
DE68911653D1
DE68911653D1 DE89311322T DE68911653T DE68911653D1 DE 68911653 D1 DE68911653 D1 DE 68911653D1 DE 89311322 T DE89311322 T DE 89311322T DE 68911653 T DE68911653 T DE 68911653T DE 68911653 D1 DE68911653 D1 DE 68911653D1
Authority
DE
Germany
Prior art keywords
antagonist
interleukin
prevent
human interleukin
reduce eosinophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE89311322T
Other languages
English (en)
Other versions
DE68911653T2 (de
Inventor
Robert L Coffman
Donna M Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68911653(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE68911653D1 publication Critical patent/DE68911653D1/de
Application granted granted Critical
Publication of DE68911653T2 publication Critical patent/DE68911653T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Head (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
DE89311322T 1988-11-03 1989-11-01 Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie. Revoked DE68911653T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03

Publications (2)

Publication Number Publication Date
DE68911653D1 true DE68911653D1 (de) 1994-02-10
DE68911653T2 DE68911653T2 (de) 1994-04-07

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89311322T Revoked DE68911653T2 (de) 1988-11-03 1989-11-01 Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.

Country Status (17)

Country Link
EP (2) EP0441891A1 (de)
JP (1) JPH07563B2 (de)
KR (1) KR960002183B1 (de)
AT (1) ATE98872T1 (de)
AU (1) AU633034B2 (de)
CA (1) CA2002144C (de)
DE (1) DE68911653T2 (de)
DK (1) DK81691D0 (de)
ES (1) ES2062032T3 (de)
HK (1) HK186196A (de)
IE (1) IE63063B1 (de)
IL (1) IL92180A (de)
MY (1) MY107386A (de)
NZ (1) NZ243939A (de)
PH (1) PH26476A (de)
WO (1) WO1990004979A2 (de)
ZA (1) ZA898322B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL176393B1 (pl) * 1992-02-06 1999-05-31 Schering Corp Monoklonalne przeciwciało lub jego fragment, które wiąże się swoiście z ludzką interleukiną-5, hybrydoma wydzielająca monoklonalne przeciwciało, które wiąże się swoiście z ludzką interleukiną-5, polipeptyd izolowany DNA, zrekombinowany wektor komórki gospodarza, humanizowane monoklonalne przeciwciało oraz sposób wytwarzania polipeptydu, sposób wytwarzania humanizowanego monoklonalnego przeciwciała i kompozycja farmaceutyczna
CA2155109A1 (en) * 1993-02-01 1994-08-18 Daniel Abramowicz Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
BR9510499B1 (pt) * 1994-12-23 2009-05-05 antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
WO2009120927A2 (en) 2008-03-28 2009-10-01 Smithkline Beecham Corporation Methods of treatment
WO2018226339A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359783B2 (de) * 1987-06-24 2002-04-17 Autoimmune, Inc. Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen

Also Published As

Publication number Publication date
HK186196A (en) 1996-10-11
CA2002144A1 (en) 1990-05-03
ATE98872T1 (de) 1994-01-15
ZA898322B (en) 1990-11-28
WO1990004979A2 (en) 1990-05-17
DK81691A (da) 1991-05-02
PH26476A (en) 1992-07-27
WO1990004979A8 (en) 2005-06-16
CA2002144C (en) 2000-03-28
ES2062032T3 (es) 1994-12-16
AU4644889A (en) 1990-05-28
EP0441891A1 (de) 1991-08-21
EP0367596B1 (de) 1993-12-22
IL92180A (en) 1997-04-15
DK81691D0 (da) 1991-05-02
EP0367596A1 (de) 1990-05-09
DE68911653T2 (de) 1994-04-07
JPH07563B2 (ja) 1995-01-11
IE893525L (en) 1990-05-03
MY107386A (en) 1995-11-30
NZ243939A (en) 1997-07-27
AU633034B2 (en) 1993-01-21
IE63063B1 (en) 1995-03-22
IL92180A0 (en) 1990-07-26
KR960002183B1 (ko) 1996-02-13
KR900701320A (ko) 1990-12-01
JPH03505211A (ja) 1991-11-14

Similar Documents

Publication Publication Date Title
ATE93144T1 (de) Methode zur verminderung der immunglobulin-ereaktion.
SG42954A1 (en) Antibody to human interleukin-6 receptor
ES2096553T3 (es) Metodo para el tratamiento de choque endotoxico en un animal mamifero.
DE68911653D1 (de) Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.
EP0216454A3 (en) Method of promoting animal growth
ES2062762T3 (es) Metodo para tratar el choque septico.
FI862978A (fi) Onkofetaalisia spesifisiä monoklonaalisia vasta-aineita, menetelmä niiden valmistamiseksi ja niiden käyttö.
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
FI924278A (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation